Literature DB >> 8385096

Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient.

M Olive1, S Untawale, R J Coffey, M J Siciliano, D M Wildrick, H Fritsche, S Pathak, L M Cherry, M Blick, P Lointier.   

Abstract

The DiFi human colorectal cancer cell line was recently established from a familial adenomatous polyposis patient with extracolonic features characteristic of the Gardner syndrome. These cells have now been propagated for 150 passages in standard culture media and vessels without feeder layers or collagen coatings. They retain features of colonic epithelial cells such as surface microvilli, secretory vesicles, and desmosomes. Cytosol of DiFi cells contains a high level (502 U/mg protein) of the mucin CA 19-9. In addition, DiFi cells produce carcinoembryonic antigen, and induce tumors in athymic mice. Cytoskeleton analysis of DiFi cells by fluorescence microscopy showed a pronounced disorganization of actin cable structure. The isozyme genetic signature of DiFi cells is unique (0.01 probability of finding the same genetic signature in a different cell line), differs from that of HeLa cells, and has expressional features seen in other colorectal cell lines. The DiFi cell karyotype is tetraploid, contains many marker chromosomes, and shows numerous episomal particles. Two copies of chromosome 18 were absent, and only a single normal chromosome 17 was found. This parallels detection of allelic losses from DiFi cell DNA at loci on chromosomes 17p and 18 using molecular (cDNA) probes. DiFi cells clearly express transcripts for the c-myc proto-oncogene, the c-myb proto-oncogene, and the p53 tumor suppressor gene. Transforming growth factor beta inhibits DiFi cell growth in soft agar and suppresses c-myc expression in these cells. The value of this cell line in the study of genetic alterations in colorectal cancer is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385096     DOI: 10.1007/bf02634191

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  53 in total

Review 1.  Familial polyposis coli: genetics, surveillance, and treatment.

Authors:  H T Lynch; B M Boman; R J Fitzgibbons
Journal:  Nebr Med J       Date:  1988-11

2.  Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta.

Authors:  R J Coffey; C C Bascom; N J Sipes; R Graves-Deal; B E Weissman; H L Moses
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

3.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

4.  Tissue culture studies on pleural effusions from breast carcinoma patients.

Authors:  R Cailleau; B Mackay; R K Young; W J Reeves
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

5.  Familial polyposis coli and Gardner syndrome--is there a difference?

Authors:  E J Gardner
Journal:  Prog Clin Biol Res       Date:  1983

6.  Chromosome banding techniques.

Authors:  S Pathak
Journal:  J Reprod Med       Date:  1976-07       Impact factor: 0.142

7.  Transforming growth factor beta 1 (TGF-beta 1) inhibits retinoblastoma gene expression but not pRB phosphorylation in TGF-beta 1-growth stimulated colon carcinoma cells.

Authors:  Z Yan; S Hsu; S Winawer; E Friedman
Journal:  Oncogene       Date:  1992-04       Impact factor: 9.867

8.  Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1.

Authors:  N M Hoosein; M K McKnight; A E Levine; K M Mulder; K E Childress; D E Brattain; M G Brattain
Journal:  Exp Cell Res       Date:  1989-04       Impact factor: 3.905

9.  A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer.

Authors:  R H Whitehead; F A Macrae; D J St John; J Ma
Journal:  J Natl Cancer Inst       Date:  1985-04       Impact factor: 13.506

10.  Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells.

Authors:  K M Mulder; A E Levine; X Hernandez; M K McKnight; D E Brattain; M G Brattain
Journal:  Biochem Biophys Res Commun       Date:  1988-01-29       Impact factor: 3.575

View more
  14 in total

1.  A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine.

Authors:  Ning Guo; Jingping Xie; H Charles Manning; Natasha G Deane; M Sib Ansari; Robert J Coffey; John Gore; Ronald R Price; Ronald M Baldwin; J Oliver McIntyre
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

2.  Digital karyotyping.

Authors:  Tian-Li Wang; Christine Maierhofer; Michael R Speicher; Christoph Lengauer; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

3.  Matrix components and behavior of human adenocarcinoma cells.

Authors:  J Turnay; N Olmo; M T López-Conejo; M A Lizarbe
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-10       Impact factor: 2.416

4.  Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.

Authors:  H Charles Manning; Nipun B Merchant; A Coe Foutch; John M Virostko; Shelby K Wyatt; Chirayu Shah; Eliot T McKinley; Jingping Xie; Nathan J Mutic; M Kay Washington; Bonnie LaFleur; Mohammed Noor Tantawy; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Mace L Rothenberg; Darryl J Bornhop; John C Gore; Robert J Coffey
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

Review 5.  Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Authors:  R Adam Smith; Saffet Guleryuz; H Charles Manning
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

6.  Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.

Authors:  Matthew V Myers; H Charles Manning; Robert J Coffey; Daniel C Liebler
Journal:  Mol Cell Proteomics       Date:  2011-12-05       Impact factor: 5.911

7.  Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.

Authors:  Shirin R Modarai; Lynn M Opdenaker; Vignesh Viswanathan; Jeremy Z Fields; Bruce M Boman
Journal:  BMC Cancer       Date:  2016-12-07       Impact factor: 4.430

8.  Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

Authors:  Eliot T McKinley; Gregory D Ayers; R Adam Smith; Samir A Saleh; Ping Zhao; Mary Kay Washington; Robert J Coffey; H Charles Manning
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

9.  Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.

Authors:  R R Tjandrawinata; R Dahiya; M Hughes-Fulford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.

Authors:  Eliot T McKinley; Ping Zhao; Robert J Coffey; M Kay Washington; H Charles Manning
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.